Di Nicolantonio et al., retrospectively analyzed objective tumor responses and survival, and the mutational status of KRAS and BRAF in 113 patients with metastatic CRC treated with cetuximab or panitumumab [9]. The gene discussed is KRAS; the disease is neoplasm.